The Stimulant Scarcity: Navigating the ADHD Medication Crisis

Why can patients fail to obtain a medicine even when a national manufacturing ceiling appears to leave room? This episode maps interacting constraints across manufacturers, ingredients, distributors, pharmacies, insurers, regulation, and a low-margin generic-drug market that may underinvest in redundancy.

The durable systems insight is that raising one legal ceiling cannot by itself repair physical supply, distribution throttles, formulation-specific shortages, or weak incentives for resilience.

Safety note: this episode contains time-sensitive medical, legal, pharmacy, and insurance claims and should not be used to make medication decisions. Shortage status and dispensing or transfer rules can change by drug, dose, jurisdiction, pharmacy, and insurer. Use a licensed clinician or pharmacist and current official sources. Sources were curated by Alex; dialogue audio was generated with NotebookLM.